Home/Filings/4/0001562135-26-000002
4//SEC Filing

EAGLE CRAIG 4

Accession 0001562135-26-000002

CIK 0001576280other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 5:58 PM ET

Size

24.6 KB

Accession

0001562135-26-000002

Insider Transaction Report

Form 4
Period: 2026-01-01
EAGLE CRAIG
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2026-01-01+1,71446,721 total
  • Exercise/Conversion

    Common Stock

    2026-01-01+13,71460,435 total
  • Exercise/Conversion

    Common Stock

    2026-01-01+1,66762,102 total
  • Exercise/Conversion

    Common Stock

    2026-01-01+5,68867,790 total
  • Exercise/Conversion

    Common Stock

    2026-01-01+2,65970,449 total
  • Tax Payment

    Common Stock

    2026-01-01$102.14/sh11,522$1,176,85758,927 total
  • Exercise/Conversion

    Restricted Stock Units

    2026-01-011,7145,143 total
    Exercise: $0.00Common Stock (1,714 underlying)
  • Exercise/Conversion

    Performance-Based Restricted Stock Units

    2026-01-0113,7140 total
    Exercise: $0.00Common Stock (13,714 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2026-01-011,6675,002 total
    Exercise: $0.00Common Stock (1,667 underlying)
  • Exercise/Conversion

    Performance-Based Restricted Stock Units

    2026-01-015,6885,688 total
    Exercise: $0.00Common Stock (5,688 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2026-01-012,65918,615 total
    Exercise: $0.00Common Stock (2,659 underlying)
Holdings
  • Performance-Based Restricted Stock Units

    Exercise: $0.00Common Stock (13,714 underlying)
    13,714
Footnotes (7)
  • [F1]These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
  • [F2]This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter.
  • [F3]Not applicable for Restricted Stock Units.
  • [F4]This represents a performance-based restricted stock unit award granted on June 7, 2023, with a performance metric and 2-year vest period that was achieved. The shares vested on January 1, 2026.
  • [F5]This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
  • [F6]This represents a performance-based restricted stock unit award granted on February 26, 2024, that a performance metric was achieved and that 33% of the shares subject to such award vested on March 1, 2025. 33% of the shares subject to the award vested on January 1, 2026, and the remaining 34% of the shares subject to the award will vest on January 1, 2027.
  • [F7]This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Issuer

Guardant Health, Inc.

CIK 0001576280

Entity typeother

Related Parties

1
  • filerCIK 0001562135

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 5:58 PM ET
Size
24.6 KB